2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5935 Translational development of hinge-optimized tandem CD19/CD20 CAR T cells demonstrates durable clinical activity in relapsed/refractory B-cell lymphoma

Zekai Mao, Ang Zhang2, Jiaqi Guo3, Xiao Zhao4, Dan Li5, Yang Cao, MD6, Fankai Meng7, Yicheng Zhang8, Weiwei Tian, MD, PhD9, Lihong Liu10, Juan Peng, MS11, Yi Liu12, Xiaoxi Zhou13, Jia Wei, MD, PhD14
1 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
2 Ninth Medical Center of Chinese PLA General Hospital, Beijing, China
3 Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, Shanxi, China
4 Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, China, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology, Senior Department of Hematology, Chinese PLA General Hospital, Beijing, China
5 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
6 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
7 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
8 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
9 Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, Shanxi, China, Sino-German Joint Oncological Research Laboratory, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Shanxi, China
10 The Fourth Hospital of Hebei Medical University, Hebei, China
11 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
12 State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology, Senior Department of Hematology, Chinese PLA General Hospital, Beijing, China
13 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
14 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China

Purpose

To develop a hinge-optimized tandem CD20/CD19 chimeric antigen receptor (CAR) T-cell product (HinTCAR2019) with enhanced antitumor activity and to evaluate its clinical safety and preliminary efficacy, either as standalone therapy or following sequential autologous stem cell transplantation (ASCT), in patients with relapsed/refractory B-cell lymphoma (r/r BCL).

Methods

HinTCAR2019 was developed through hinge-region optimization and evaluated using in vitro functional assays and lymphoma xenograft models. Clinical safety and efficacy were subsequently assessed in a multicenter phase Ia/Ib study including 50 patients with r/r BCL treated with HinTCAR2019 alone (n=29) or following sequential ASCT (n=21).

Results

Preclinical studies demonstrated that HinTCAR2019 achieved enhanced expansion and cytotoxic activity in vitro together with durable antitumor efficacy in lymphoma xenograft models. Transcriptomic analyses further supported enhanced T-cell activation and effector function.

Clinically, no dose-limiting toxicities were observed. Grade ≥3 cytokine release syndrome occurred in 2% of patients, and no grade ≥3 immune effector cell-associated neurotoxicity syndrome was reported. CAR T-cell expansion and pharmacokinetic profiles were reproducible across treated patients. The best overall response rate was 88%, including a complete response rate of 56%. After a median follow-up of 25.2 months, median progression-free survival (PFS) and overall survival (OS) were not reached, with estimated 3-year PFS and OS rates of 65.3% and 74.5%, respectively. Among patients receiving sequential ASCT followed by HinTCAR2019, the estimated 3-year PFS and OS rates were 85.7% and 95.2%, respectively, without an apparent increase in treatment-related toxicities.

Conclusions

HinTCAR2019 demonstrated potent preclinical activity together with favorable safety and durable clinical responses in heavily pretreated patients with r/r BCL. These findings establish the clinical feasibility of hinge optimization for dual-target CAR T-cell therapy and support further prospective evaluation of HinTCAR2019 in patients with r/r B-cell lymphoma.

Zekai Mao: No relevant conflicts of interest to declare.